Spironolactone (SPL) is a reversible mineralocorticoid receptor (MR) and androgen receptor (AR) antagonist which attracts pharmacotherapeutic interest not only because of its beneficial effects in heart failure but also because of the pathogenetic roles of MR and AR activities in neuropsychiatric diseases. Recently, beneficial and rapid-onset effects of SPL have been documented in a case series of women with fibromyalgia syndrome (FMS). To reaffirm this observation, we performed a double-blind placebo-controlled randomized clinical trial (RCT).

中文翻译：

---

高剂量螺内酯治疗纤维肌痛 (RCT) 缺乏有效性

螺内酯 (SPL) 是一种可逆的盐皮质激素受体 (MR) 和雄激素受体 (AR) 拮抗剂，它吸引了药物治疗的兴趣，不仅因为其对心力衰竭的有益作用，而且还因为 MR 和 AR 活动在神经精神疾病中的致病作用。最近，在一系列患有纤维肌痛综合征 (FMS) 的妇女的病例系列中记录了 SPL 的有益和快速起效作用。为了重申这一观察结果，我们进行了一项双盲安慰剂对照随机临床试验 (RCT)。